Next™ BriefFactor XI Anticoagulants and Bleeding-Safe Stroke Prevention
Buy Now
Meticulous Next™HealthcareNov 2026108 ppMRN-1807

Factor xi anticoagulants Market Outlook 2026–2035: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

Brief ID: MRN-1807Format: PDF + Summary DeckDelivery: InstantHorizon: 9-yr horizonSignal: High-impact
Buy Now · $1,250
Adoption maturity (indexed)
Mainstream inflection: ~2030
Horizon: 2026–2035 · Signal: High-impact
9 yrs
Forward horizon
~2030
Mainstream inflection
High impact
Signal strength

What This Brief Covers

This Meticulous Next™ brief examines factor XI anticoagulants, the new class of blood thinners that target factor XIa to prevent clots with less bleeding. It tests how far the first approval and the trials of competing molecules move factor XI inhibitors into stroke and atrial fibrillation care by 2035, and what that means for pharma firms, cardiologists and payers.

The first approval has arrived. Bayer announced positive OCEANIC-STROKE results for asundexian on 23 November 2025. In 12,327 patients after a non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack, asundexian 50 mg once daily added to antiplatelet therapy cut ischaemic stroke to 6.2% from 8.4% on placebo, a 26% relative reduction, with major bleeding of 1.9% against 1.7%, a difference that was not significant. China approved the medicine as Sunharbo on 26 October 2026, and the US Food and Drug Administration approved it on 9 November 2026. The conclusion is that a factor XIa inhibitor has now shown stroke prevention without a clear rise in major bleeding, and the class has moved from trials to clinical use in under a year.

The label is narrow. The approval covers secondary prevention after a non-cardioembolic stroke or high-risk transient ischaemic attack with antiplatelet therapy, and it does not cover atrial fibrillation. Bayer lists a price of USD 748.50 for a 30-day supply, and stroke specialists expect cost to be the main limit and early uptake to be slow. The conclusion is that the first market is secondary stroke prevention in specialist centres, and the larger atrial fibrillation and thrombosis markets depend on other trials.

The competing molecules face a mixed record. Milvexian, from Bristol Myers Squibb and Johnson & Johnson, saw its acute coronary syndrome trial fail in August 2026, with its stroke and atrial fibrillation trials due to report around the end of 2026. Novartis holds an injectable factor XI antibody through its purchase of Anthos Therapeutics. The conclusion is that the near term field is narrow, and the next readouts decide whether the class widens beyond stroke.

The brief treats factor XI anticoagulants as a high-impact signal with a nine year horizon to 2035. It identifies which developers, payers and care providers capture value as the class expands. It is a focused 108-page decision brief that presents an indicative trajectory rather than a segmented market model.

Brief Snapshot
ParameterDetails
Forward horizon2026–2035 (9 years)
Emerging forceFactor XI inhibitors
Technology readinessOne approved factor XIa inhibitor in the United States and China, with further trials of milvexian and an injectable antibody ongoing
Indicative market size & forecastThe factor XI anticoagulants market, covering oral and injectable factor XI and factor XIa inhibitors prescribed for stroke prevention, atrial fibrillation and thrombosis, and excluding direct oral anticoagulants, warfarin, heparins and antiplatelet medicines, is valued at USD 0.03–0.08 billion in 2026 and is projected to reach USD 2.06–5.50 billion by 2035, at a CAGR of 60%
Mainstream inflection~2030, when atrial fibrillation and further stroke trial data, payer coverage and guidelines support wider prescribing
Signal strengthA positive phase 3 stroke trial and first approvals, against a narrow label, a high price and mixed competitor results
Primary beneficiariesDevelopers with approved products and positive trials; stroke specialists with a lower-bleeding option; payers with clear coverage criteria
Brief length / format108 pages · PDF + executive summary deck · instant delivery

Understanding the Technology

Factor XI is a protein in the clotting cascade that matters for clots inside vessels but less for stopping bleeding after injury. Blocking its active form, factor XIa, aims to prevent stroke and thrombosis with less bleeding than current anticoagulants, which act on factor Xa or thrombin. The conclusion is that the class targets the main weakness of existing anticoagulants, which is bleeding.

Asundexian is a once-daily oral small molecule. In OCEANIC-STROKE, ischaemic stroke fell to 6.2% from 8.4%, disabling stroke to 2.1% from 3.0%, and major bleeding was 1.9% against 1.7%, though gastrointestinal bleeding was higher at 2.7 against 2.1 per 100 patient-years. The conclusion is that the bleeding advantage is clear against more intensive therapy but not absolute, and labelling and monitoring will reflect it.

The class has had setbacks. The milvexian stroke trial at phase II missed its primary endpoint, its acute coronary syndrome trial failed in August 2026, and asundexian did not succeed in an atrial fibrillation trial. The conclusion is that benefit depends on the condition, and results in stroke do not transfer automatically to atrial fibrillation.

The limits are label scope, price, drug interactions and the lack of results in atrial fibrillation. The brief tests each limit against the evidence to 2035.

Market Outlook

The factor XI anticoagulants market, covering oral and injectable factor XI and factor XIa inhibitors prescribed for stroke prevention, atrial fibrillation and thrombosis, and excluding direct oral anticoagulants, warfarin, heparins and antiplatelet medicines, is valued at USD 0.03–0.08 billion in 2026 and is projected to reach USD 2.06–5.50 billion by 2035, at a CAGR of 60%.

The 2026 base rests on oral and injectable factor XI and factor XIa inhibitors prescribed for stroke prevention, atrial fibrillation and thrombosis at current prices, which excludes direct oral anticoagulants, warfarin, heparins and antiplatelet medicines. Growth follows the number of patients on treatment, the share of conditions covered by labels and the net price after rebates.

The forecast is sensitive to results of the milvexian and other trials, regulatory decisions in Europe and Japan, payer coverage and guideline recommendations.

Scenarios

The base case assumes at least one further trial supports a wider label and payers cover the stroke indication, bringing the inflection to 2030 and a 2035 value near the middle of the range. An accelerated case assumes positive atrial fibrillation results and fast payer coverage, moving the inflection to 2028 and lifting the 2035 value to the top of the range. A delayed case assumes further trials fail and cost limits uptake, moving the inflection to 2033 and holding growth at the bottom of the range.

Factors Behind Growth

Growth drivers

  • Bleeding risk with current anticoagulants.
  • Positive phase 3 stroke prevention results.
  • First approvals in the United States and China.
  • Large population needing antithrombotic therapy.

Enablers

  • Priority review by regulators.
  • Once-daily oral dosing.
  • Several molecules and modalities in development.
  • Specialist stroke centre networks.

Restraints and barriers

  • Narrow first label.
  • Price and reimbursement.
  • Mixed trial results across conditions.
  • Drug interactions and liver enzyme findings.

The Forces at Play

The direction of factor XI anticoagulants is set by trial results beyond stroke, regulatory decisions, payer coverage and guideline recommendations.

The brief assesses standards and policy, company and investor funding, technology readiness, product readiness and customer readiness, and rates each force for direction, speed and confidence.

Adoption Outlook

How the shift is likely to unfold across three time horizons.

Near term2026–2029
Launch in stroke

Asundexian launches in secondary stroke prevention while milvexian and other trials report.

Mid term2029–2032
Label expansion

Atrial fibrillation and further stroke results decide whether labels widen.

Long term2032–2035
Established class

Factor XI inhibitors hold a defined place beside direct oral anticoagulants.

Latest Strategic Developments

DateDevelopmentTypeSignificance
Nov 2025Bayer reports that asundexian met its primary efficacy and safety endpoints in the phase III OCEANIC-STROKE trialTrial resultShows stroke prevention without a significant rise in major bleeding
May 2026The FDA accepts the asundexian new drug application with Priority Review, and Japan accepts the submissionRegulatoryStarts the first regulatory reviews
Jun 2026The European Medicines Agency accepts the asundexian marketing authorisation applicationRegulatoryOpens the European review
Aug 2026The milvexian phase III trial in acute coronary syndrome failsTrial resultNarrows the competitor field
Oct 2026China approves asundexian as Sunharbo on 26 OctoberApprovalGives the first approval of a factor XIa inhibitor
Nov 2026The FDA approves Sunharbo on 9 November for secondary stroke preventionApprovalOpens the United States market

Key Players & Competitive Landscape

The key participants in factor XI anticoagulants include Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Daiichi Sankyo Company, Limited, Sanofi, Teva Pharmaceutical Industries Limited, Viatris Inc., Boston Scientific Corporation, Abbott Laboratories, Medtronic plc, HCA Healthcare, Inc., Cardinal Health, Inc., McKesson Corporation, CVS Health Corporation, The Cigna Group, UnitedHealth Group Incorporated and City Therapeutics, among others.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as the class expands.

Competitive intensity is low today with one approved product and rises with milvexian and other entrants, with entry barriers set by outcome trial size, safety evidence and payer contracting.

ArchetypeRepresentative playersPositionOutlook
Factor XI developersBayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.Factor XI and XIa inhibitorsComplete trials and extend labels
Incumbent anticoagulant makersPfizer Inc., Daiichi Sankyo Company, Limited, Sanofi, Teva Pharmaceutical Industries Limited, Viatris Inc.Direct oral anticoagulants, heparins and genericsDefend share on price and familiarity
Stroke prevention device makersBoston Scientific Corporation, Abbott Laboratories, Medtronic plcCardiac and stroke devicesCompete with drug options for atrial fibrillation stroke prevention
Providers and distributorsHCA Healthcare, Inc., Cardinal Health, Inc., McKesson CorporationHospitals and drug distributionHandle early stroke centre use
PayersCVS Health Corporation, The Cigna Group, UnitedHealth Group IncorporatedCoverage and formulariesSet access and price

Where value migrates.

In 2026 value sits with the first approved product and stroke centres that prescribe it. By 2030 it moves toward developers with wider labels and toward payers that set coverage by risk. By 2035 it settles with products holding guideline positions in stroke and atrial fibrillation. Margins narrow as competing molecules arrive and generic anticoagulants hold the broad market.

Who Will Win — and Why

The archetypes best positioned to capture value as the shift matures.

Developers with positive trials beyond stroke

Wider labels expand the treated population.

Stroke specialists and centres

A lower-bleeding option fits recurrent stroke care.

Payers with clear coverage criteria

Clear rules direct spend to benefit.

Regulatory Landscape

JurisdictionMilestoneIndicative timingEffect on adoption
US Food and Drug AdministrationApproval of Sunharbo for secondary stroke preventionNovember 2026Opens the United States market
China National Medical Products AdministrationApproval of SunharboOctober 2026Gives the first approval of a factor XIa inhibitor
European Medicines AgencyMarketing authorisation application acceptedJune 2026Opens the European review
Japan Ministry of Health, Labour and WelfareSubmission acceptedMay 2026Opens the Japanese review
US Food and Drug AdministrationNew drug application accepted with Priority ReviewMay 2026Starts the United States review

Investment Signals

Bleeding risk with current anticoagulants, positive stroke results, first approvals and a large treatable population support growth, while the narrow first label, price and reimbursement, mixed results across conditions and drug interactions hold back the pace.

The milvexian stroke and atrial fibrillation readouts, a European decision, a payer coverage ruling or a guideline update would shift the pace. The brief therefore tracks four indicators: trial readouts, regulatory decisions, coverage decisions and prescription volumes.

Launch in stroke, then label expansion, then an established class is the expected order of change.

Questions This Brief Answers

01What are factor XI anticoagulants, and how do they differ from current blood thinners?
02What is the market size in 2026, and what is the forecast to 2035?
03What did the phase 3 stroke trial show, and what was approved?
04What factors are driving growth, and what barriers remain?
05Which key participants are active, and which archetypes are positioned to win?
06What are the latest developments?
07How will trials beyond stroke, price and coverage shape the market between 2026 and 2035?
08What should pharma firms, clinicians, payers and investors do now?

Strategic Implications

  • Pharma firms: support specialist launch with access programmes and plan trials in atrial fibrillation and other conditions to widen labels.
  • Cardiologists and neurologists: use the new option for recurrent stroke patients who need lower bleeding risk and track gastrointestinal bleeding.
  • Payers: define coverage by stroke risk and review it when new trial data arrive.
  • Providers and distributors: prepare stroke centre pathways and supply for a new class.
  • Investors: weigh launch uptake against the milvexian readouts and the pace of label expansion.
Analyst Perspective

"A blood thinner earns trust by preventing the next clot without causing the next bleed."

Lead Foresight Analyst
Healthcare & Life Sciences · Meticulous Next™

Table of Contents

Access & Licensing

A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.

Single Brief
$1,250
One named user
Full PDF brief
Executive summary deck
One named user
Free outlook update
★ Most Popular
Team License
$1,750
Up to 10 users
Access for 2–10 users
Internal sharing rights
30-minute analyst briefing
Enterprise
$2,050
Organization-wide
Organization-wide access
Unlimited users
Priority analyst access
Custom extracts
Included with
every brief
Analyst-reviewed foresightMulti-signal validationInstant deliveryFree outlook updates

Frequently Asked Questions

Search Market Intelligence

Search across reports, blogs, press releases, and industries